Skip to main content

Table 3 Low back pain potential systemic biomarkers measured before and after therapy

From: Subjective assessment and biochemical evaluation of traction therapy in women with chronic low back pain: does body mass index matter? A clinical study

 

Normal-weight (n = 13)

Obesity (n = 15)

 

PRE therapy

POST therapy

P value c

PRE therapy

POST therapy

p value c

Leptin [ng/ml]

14.0 ± 5.7

14.3 ± 9.5

0.9165

41.7 ± 10.0

42.3 ± 11.3

0.5701

Adipsin/CFD [ng/ml]

7.09 ± 1.87

7.25 ± 1.43

0.7535

8.02 ± 1.17

8.13 ± 1.00

0.6970

GDF-15 [pg/ml]

451 ± 190

417 ± 178

0.0392

458 ± 206

557 ± 321

0.0356

CS-846 [ng/ml]

20.1 ± 4.3

20.0 ± 2.7

0.8613

43.6 ± 83.9

42.1 ± 80.4

0.0356

Neuropeptide Y [pg/ml]

598 ± 144

580 ± 114

0.5953

865 ± 391

894 ± 454

0.6910

  1. c the Wilcoxon rank-sum test or the paired t-test
  2. Data are presented as the mean ± SD.
  3. CFD, Complemet Factor D, GDF-15, growth and differentiation factor 15. CS-846, aggrecan chondroitin sulfate 846 epitope.
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us